These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 22976766

  • 1. Dynamic changes of lipid profile in Romanian patients with Gaucher disease type 1 under enzyme replacement therapy: a prospective study.
    Zimmermann A, Grigorescu-Sido P, Rossmann H, Lackner KJ, Drugan C, Al Khzouz C, Bucerzan S, Naşcu I, Zimmermann T, Leucuţa D, Weber MM.
    J Inherit Metab Dis; 2013 May; 36(3):555-63. PubMed ID: 22976766
    [Abstract] [Full Text] [Related]

  • 2. The role of high density lipoprotein in Type 1 Gaucher disease.
    Watad S, Abu-Saleh N, Yousif A, Agbaria A, Rosenbaum H.
    Blood Cells Mol Dis; 2018 Feb; 68():43-46. PubMed ID: 27876360
    [Abstract] [Full Text] [Related]

  • 3. [Effect of enzyme replacement therapy on lipid profile in patients with Gaucher's disease].
    Alfonso P, Cenarro A, Pérez-Calvo JI, Puzo J, Giralt M, Giraldo P, Pocoví M.
    Med Clin (Barc); 2003 May 10; 120(17):641-6. PubMed ID: 12747811
    [Abstract] [Full Text] [Related]

  • 4. Changes in the atherogenic profile of patients with type 1 Gaucher disease after miglustat therapy.
    Puzo J, Alfonso P, Irun P, Gervas J, Pocovi M, Giraldo P.
    Atherosclerosis; 2010 Apr 10; 209(2):515-9. PubMed ID: 19959168
    [Abstract] [Full Text] [Related]

  • 5. Relationship Between Glucocerebrosidase Activity and Clinical Response to Enzyme Replacement Therapy in Patients With Gaucher Disease Type I.
    Gras-Colomer E, Martínez-Gómez MA, Climente-Martí M, Fernandez-Zarzoso M, Almela-Tejedo M, Giner-Galvañ V, Marcos-Rodríguez JA, Rodríguez-Fernández A, Torralba-Cabeza MÁ, Merino-Sanjuan M.
    Basic Clin Pharmacol Toxicol; 2018 Jul 10; 123(1):65-71. PubMed ID: 29418074
    [Abstract] [Full Text] [Related]

  • 6. Cholelithiasis in Patients with Gaucher Disease type 1: Risk Factors and the Role of ABCG5/ABCG8 Gene Variants.
    Zimmermann A, Popp RA, Al-Khzouz C, Bucerzan S, Naşcu I, Leucuta D, Galle PR, Grigorescu-Sido P.
    J Gastrointestin Liver Dis; 2016 Dec 10; 25(4):447-455. PubMed ID: 27981300
    [Abstract] [Full Text] [Related]

  • 7. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis.
    Mistry PK, Deegan P, Vellodi A, Cole JA, Yeh M, Weinreb NJ.
    Br J Haematol; 2009 Nov 10; 147(4):561-70. PubMed ID: 19732054
    [Abstract] [Full Text] [Related]

  • 8. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL, Zhang YH, Zang Y, Shi HP, Zhang WM, Hu YM.
    Zhonghua Er Ke Za Zhi; 2006 Sep 10; 44(9):653-6. PubMed ID: 17217655
    [Abstract] [Full Text] [Related]

  • 9. Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
    Mistry PK, Batista JL, Andersson HC, Balwani M, Burrow TA, Charrow J, Kaplan P, Khan A, Kishnani PS, Kolodny EH, Rosenbloom B, Scott CR, Weinreb N.
    Am J Hematol; 2017 Sep 10; 92(9):929-939. PubMed ID: 28569047
    [Abstract] [Full Text] [Related]

  • 10. Improvement of life quality measured by Lansky Score after enzymatic replacement therapy in children with Gaucher disease type 1.
    Cerón-Rodríguez M, Barajas-Colón E, Ramírez-Devars L, Gutiérrez-Camacho C, Salgado-Loza JL.
    Mol Genet Genomic Med; 2018 Jan 10; 6(1):27-34. PubMed ID: 29471591
    [Abstract] [Full Text] [Related]

  • 11. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment.
    Weinreb NJ, Camelo JS, Charrow J, McClain MR, Mistry P, Belmatoug N, International Collaborative Gaucher Group (ICGG) Gaucher Registry (NCT00358943) investigators.
    Mol Genet Metab; 2021 Feb 10; 132(2):100-111. PubMed ID: 33485799
    [Abstract] [Full Text] [Related]

  • 12. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL.
    Clin Ther; 2012 Feb 10; 34(2):259-71. PubMed ID: 22264444
    [Abstract] [Full Text] [Related]

  • 13. Endocrinological and metabolic profile of Gaucher disease patients treated with enzyme replacement therapy.
    Kilic A, Emecen Sanli M, Ozsaydı Aktasoglu E, Gokalp S, Biberoğlu G, Inci A, Okur I, Suheyl Ezgu F, Tumer L.
    J Pediatr Endocrinol Metab; 2024 May 27; 37(5):413-418. PubMed ID: 38624096
    [Abstract] [Full Text] [Related]

  • 14. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.
    Smith L, Rhead W, Charrow J, Shankar SP, Bavdekar A, Longo N, Mardach R, Harmatz P, Hangartner T, Lee HM, Crombez E, Pastores GM.
    Mol Genet Metab; 2016 Feb 27; 117(2):164-71. PubMed ID: 26043810
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage.
    Giraldo P, Irún P, Alfonso P, Dalmau J, Fernández-Galán MA, Figueredo A, Hernández-Rivas JM, Julia A, Luño E, Marín-Jimenez F, Martín-Nuñez G, Montserrat JL, de la Serna J, Vidaller A, Villalón L, Pocovi M.
    Blood Cells Mol Dis; 2011 Jan 15; 46(1):115-8. PubMed ID: 20934891
    [Abstract] [Full Text] [Related]

  • 16. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
    Wenstrup RJ, Kacena KA, Kaplan P, Pastores GM, Prakash-Cheng A, Zimran A, Hangartner TN.
    J Bone Miner Res; 2007 Jan 15; 22(1):119-26. PubMed ID: 17032149
    [Abstract] [Full Text] [Related]

  • 17. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
    Heitner R, Arndt S, Levin JB.
    S Afr Med J; 2004 Aug 15; 94(8):647-51. PubMed ID: 15352589
    [Abstract] [Full Text] [Related]

  • 18. Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage-targeted enzyme replacement therapy.
    Stein P, Malhotra A, Haims A, Pastores GM, Mistry PK.
    J Inherit Metab Dis; 2010 Dec 15; 33(6):769-74. PubMed ID: 20683668
    [Abstract] [Full Text] [Related]

  • 19. Haemostatic abnormalities in treatment-naïve patients with Type 1 Gaucher's disease.
    Mitrovic M, Antic D, Elezovic I, Janic D, Miljic P, Sumarac Z, Nikolic T, Suvajdzic N.
    Platelets; 2012 Dec 15; 23(2):143-9. PubMed ID: 21767238
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of high density lipoprotein as a circulating biomarker of Gaucher disease activity.
    Stein P, Yang R, Liu J, Pastores GM, Mistry PK.
    J Inherit Metab Dis; 2011 Apr 15; 34(2):429-37. PubMed ID: 21290183
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.